Cytek Biosciences (CTKB) to Release Earnings on Thursday

Cytek Biosciences (NASDAQ:CTKB) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cytek Biosciences to post earnings of $0.02 per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Cytek Biosciences Stock Down 0.7%

CTKB stock opened at $4.36 on Wednesday. The firm has a 50 day moving average of $4.97 and a two-hundred day moving average of $4.55. Cytek Biosciences has a 12 month low of $2.37 and a 12 month high of $6.18. The company has a market capitalization of $557.47 million, a price-to-earnings ratio of -43.60 and a beta of 1.30.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Cytek Biosciences by 2.5% during the fourth quarter. Invesco Ltd. now owns 398,797 shares of the company’s stock worth $2,014,000 after buying an additional 9,671 shares during the last quarter. Numerai GP LLC raised its stake in Cytek Biosciences by 75.4% during the 4th quarter. Numerai GP LLC now owns 186,764 shares of the company’s stock valued at $943,000 after purchasing an additional 80,269 shares during the last quarter. Millennium Management LLC boosted its holdings in Cytek Biosciences by 39.0% in the 4th quarter. Millennium Management LLC now owns 4,752,447 shares of the company’s stock valued at $24,000,000 after purchasing an additional 1,334,065 shares during the period. Price T Rowe Associates Inc. MD grew its position in Cytek Biosciences by 12.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,793 shares of the company’s stock worth $353,000 after purchasing an additional 7,658 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Cytek Biosciences by 527.6% during the 4th quarter. Russell Investments Group Ltd. now owns 1,001,127 shares of the company’s stock worth $5,056,000 after purchasing an additional 841,614 shares during the period. 69.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Zacks Research downgraded shares of Cytek Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. TD Cowen reiterated a “buy” rating on shares of Cytek Biosciences in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Monday, December 29th. Piper Sandler reduced their target price on Cytek Biosciences from $8.00 to $7.50 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, Morgan Stanley began coverage on Cytek Biosciences in a report on Monday, December 1st. They set an “equal weight” rating and a $6.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.50.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.